Google
ANVS 株価分析 — Annovis Bio Inc (Healthcare >> Biotechnology)
ANVS に関するよくある質問
ANVSのROE（自己資本利益率）は？
Annovis Bio IncのROEは-1,309.11%です。
ANVSの配当利回りは？
Annovis Bio Incの配当利回りは0.00%です。
ANVSの品質スコア（Quality Score）は？
当社のAIはANVSの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
ANVSは今が買い時ですか？
当社AIのタイミングスコアは100点中51点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
ANVSはどのセクターに属しますか？
Annovis Bio IncはHealthcare >> Biotechnologyセクターに分類されます（NYSE市場）
ANVS AI Analysis Summary
Our AI summary for ANVS: Annovis Bio Inc (NYSE), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -1,309.11%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 51/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.87
Price
0.15
(8.72%)
Day Change
|
|
|---|
ANVS, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROEが昨年度比で低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.87 |
| PBV / Sector |
23.41 / 44,022.72
|
| Earning Per Share | -1.05 |
| PE / Sector |
N/A / 19.17
|
| PEG or PE/Growth / Sector |
N/A / 1.24
|
| Average 1M Daily Value |
1.31 M
GREAT
|
| Average 1W Daily Value |
0.90 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-05 07:59:49 |
| Symbol | ANVS |
| Name | ANNOVIS BIO INC |
| Sector | Healthcare >> Biotechnology |
| Market | NYSE |
| Listed Shares | 42.54 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 73.17 / 9,586.08 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 101 Lindenwood Drive, Malvern, PA, United States, 19355
Phone: 484 875 3192
Website: https://www.annovisbio.com
Sector: Healthcare >> Biotechnology
Description: Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
